Micro Emerging Active

AZN receives EU approval for Imfinzi in early gastric/gastroesophageal cancers

New narrative with limited coverage — still forming.

Score

0.2

Velocity

▲ 0.0

Articles

Sources

Top Movers

Ticker	Sector	Change
III	Technology	+9.2%
AZN	Healthcare	+0.3%

Mar 27, 2026

AstraZeneca stock jumps 4% after surprise trial win for lung disease drug … Bullish

Mar 26, 2026

Agilent Announces Expanded Approval Of PD-L1 IHC 22C3 PharmDx In Esophageal Or … Neutral

Mar 25, 2026

AstraZeneca (AZN) Announces EU Approval of Imfinzi for Early Gastric/Gastroesophageal Cancers Neutral

Ticker	Sector	Change
III	Technology	+9.2%
AZN	Healthcare	+0.3%

First SeenMar 25, 2026

Last UpdatedMar 25, 2026